Paul K Wotton
CIK 1300997 · President and CEO · last filed 2026-05-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$28.85M
Companies
5
Total Filings
63
Lifetime Open-Market Net
-$4.31M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VCEL | Director | 18,802 | $46.62 | $876.5K | -$2.63M | 21 | 2026-05-13 |
| Ocata Therapeutics, Inc. (OCAT) Delisted | President and CEO | 0 | — | — | $0 | 3 | 2016-02-11 |
| ANTARES PHARMA, INC. (ATRS) Delisted | President and CEO | 670,734 | $5.59 | $3.75M | -$1.72M | 14 | 2014-02-24 |
| AIS | President and CEO | 482,620 | $57.96 | $27.97M | $35.1K | 17 | 2012-05-21 |
| GENAERA CORP (GENR) Delisted | Director | — | — | — | $0 | 2 | 2008-08-15 |
Recent Filings · Page 4 of 7
63 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-02-24 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | +7,000 | -$16.0K | EDGAR |
| 2014-02-13 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | −45,000 | -$49.0K | EDGAR |
| 2014-01-17 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$105.3K | EDGAR |
| 2013-12-10 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$224.6K | EDGAR |
| 2013-10-03 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$129.0K | EDGAR |
| 2013-09-05 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$136.9K | EDGAR |
| 2013-08-05 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$137.1K | EDGAR |
| 2013-07-03 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$127.5K | EDGAR |
| 2013-06-05 | ANTARES PHARMA, INC. (ATRS) Delisted | Mixed | — | -$438.6K | EDGAR |
| 2013-05-24 | ANTARES PHARMA, INC. (ATRS) Delisted | Grant (A) | +185,186 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.